TITLE

Qualitative assessment of attributes and ease of use of the ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and COPD

AUTHOR(S)
Svedsater, Henrik; Dale, Peter; Garrill, Karl; Walker, Richard; Woepse, Mark W.
PUB. DATE
January 2013
SOURCE
BMC Pulmonary Medicine;2013, Vol. 13 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background Medications for respiratory disorders including asthma and chronic obstructive pulmonary disease (COPD) are typically delivered to the lung by means of a handheld inhaler. Patient preference for and ability to use the inhaler may influence their adherence to maintenance therapy, and adherence may affect treatment outcomes. In this study, patient experience of using a dry powder inhaler (DPI), the ELLIPTAâ„¢ DPI, in clinical trials of a new maintenance therapy for asthma and COPD was investigated. The ELLIPTA DPI has been designed to contain two separate blister strips from which inhalation powder can be delivered, and to be simple to use with a large, easy-to-read dose counter. Methods Semi-structured, in-depth, qualitative interviews were carried out 2-4 weeks after patients had completed one of six phase IIIa clinical trials using the ELLIPTA DPI. Interview participants were asked about their satisfaction with various attributes of the inhaler and their preference for the ELLIPTA DPI relative to currently-prescribed inhalers, and responses were explored using an inductive content analysis approach. Participants also rated the performance of the inhaler on several criteria, using a subjective 1-10 scale. Results with asthma (n = 33) and COPD (n = 42) reported high levels of satisfaction with the ELLIPTA DPI. It was frequently described as straightforward to operate and easy to use by interview participants. Ergonomic design, mouthpiece fit, and dose counter visibility and ease of interpretation emerged as frequently cited drivers of preference for the ELLIPTA DPI compared with their current prescribed inhaler. Of participants with asthma, 71% preferred the ELLIPTA DPI to DISKUSâ„¢ and 60% to metered dose inhalers. Of participants with COPD, 86% preferred the ELLIPTA DPI to DISKUS, 95% to HandiHalerâ„¢, and 85% to metered dose inhalers. Overall average performance scores were >9 (out of 10) in participants with asthma and COPD. Conclusion ELLIPTA DPI was associated with high patient satisfaction and was preferred to other inhalers by interview participants with asthma and COPD. The development of an inhaler that is regarded as easy and intuitive to use may have positive implications for adherence to therapy in asthma and COPD.
ACCESSION #
93607635

 

Related Articles

  • Primer on inhalers and nebulizers. Salvo, Marissa; Barjami, Artild; Baughmaii-Oprica, Christopher // Drug Topics;Aug2015, Vol. 159 Issue 8, p38 

    With various delivery methods of asthma and chronic obstructive pulmonary disease (COPD) medications available, pharmacists need to be well versed on the administration and care instructions for each device. Inhaler technique varies depending on the device; therefore, patients may...

  • The adequacy of inhaler technique in patients with chronic obstructive pulmonary disease and asthma attending a tertiary care hospital in Navi Mumbai. Das, Akanksha; Uppe, Abhay; Sinha, Kanishk; T. K., Jayalakshmi; Nair, Girija; Nagpal, Amit // Indian Journal of Allergy Asthma & Immunology;Jul-Dec2016, Vol. 30 Issue 2, p95 

    Objectives: Chronic obstructive pulmonary disease (COPD) and asthma are major concerns to health-care system. Improper inhaler device used (metered dose inhaler/dry powder inhaler) is one of the major causes associated with inadequate control of the disease. This study was performed to evaluate...

  • Budesonide/Formoterol Pressurized Metered-Dose Inhaler. Lyseng-Williamson, Katherine A. // Drugs;2009, Vol. 69 Issue 11, p1459 

    The corticosteroid budesonide and the rapid-onset, long-acting β2-adrenoceptor agonist formoterol have been combined into a single pressurized metered-dose inhaler (pMDI) for use in patients with chronic obstructive pulmonary disease (COPD). Well designed 6- and 12-month clinical trials,...

  • Using exhaled NO concentrations to adjust inhaled corticosteroid dose maintained asthma control and reduced the dose. Smith, A. D.; Cowan, J. O.; Brassett, K. P.; Taylor, R. // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p20 

    The article reports on a study to determine whether optimizing the inhaled corticosteroid dose using the fraction of nitric oxide in exhaled air can reduce asthma exacerbations and the daily dosage compared to the use of standard criteria for patients with chronic asthma. Patients aged 12-75...

  • Commentary. Rees, P. John // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p20 

    The article comments on a study by A. D. Smith and colleagues to determine whether optimizing the inhaled corticosteroid dose using the fraction of nitric oxide in exhaled air can reduce asthma exacerbations and the daily dosage compared to the use of standard criteria for patients with chronic...

  • Review: anticholinergics in addition to β2 agonists improve outcome in children and adults with acute asthma. Rodrigo, G. J.; Castro-Rodriguez, J. A. // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p21 

    The article reports on a study which reviews various research to determine whether inhaled anticholinergic agents plus β2 agonists can enhanced outcome in children and adults with acute asthma exacerbations compared to β2 agonists alone. The studies examined used randomized controlled...

  • Commentary. Thien, Frank // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p21 

    The article comments on a study by G. J. Rodrigo and colleagues which reviews various research to determine whether inhaled anticholinergic agents plus β2 agonists can enhanced outcome in children and adults with acute asthma exacerbations compared to β2 agonists alone. The meta-analysis...

  • Utilization and responsiveness of the asthma control test (ACT) at the initiation of therapy for patients with asthma: a randomized controlled trial.  // BMC Pulmonary Medicine;2012, Vol. 12 Issue 1, p14 

    The article presents information on a study which evaluates the effectiveness of the asthma control test (ACT) to find out the changes at the initiation of therapy and its utilization in the initiation of asthma treatment. The randomized controlled trial included patients who had not received...

  • High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial. Mahajan, Amit K.; Diette, Gregory B.; Hatipoğlu, Umur; Bilderback, Andrew; Ridge, Alana; Harris, Vanessa Walker; Dalapathi, Vijay; Badlani, Sameer; Lewis, Stephanie; Charbeneau, Jeff T.; Naureckas, Edward T.; Krishnan, Jerry A. // Respiratory Research;Sep2011, Vol. 12 Issue 9, p1 

    Background: High frequency chest wall oscillation (HFCWO) is used for airway mucus clearance. The objective of this study was to evaluate the use of HFCWO early in the treatment of adults hospitalized for acute asthma or chronic obstructive pulmonary disease (COPD).Methods:...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics